![JMA – Ninja & Deep Jandu [Official MV] Kaptaan](https://i.ytimg.com/vi/-dsfIh319s0/maxresdefault.jpg "JMA – Ninja & Deep Jandu [Official MV] Kaptaan")
(*6*)
(*4*)
Español
Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to supply for a single booster dose of the vaccine in youngsters 6 months through 4 years of age at the least 2 months after completion of main vaccination with three doses of the monovalent (single pressure) Pfizer-BioNTech COVID-19 Vaccine.
What Parents and Caregivers Need to Know:
- Children 6 months through 4 years of age who accomplished their three-dose main collection with the monovalent Pfizer-BioNTech COVID-19 Vaccine greater than two months in the past are actually eligible to obtain a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.
- Since December 2022, youngsters 6 months through 4 years of age who obtain the primary two doses with monovalent Pfizer-BioNTech COVID-19 Vaccine ought to full their three-dose main collection with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. These youngsters on this age group aren’t eligible for a booster dose of a bivalent vaccine presently and are anticipated to have safety towards essentially the most severe COVID-19 outcomes. Today’s authorization is for these youngsters 6 months through 4 years of age who accomplished their 3-dose main vaccination collection with the monovalent Pfizer-BioNTech COVID-19 Vaccine, earlier than the Pfizer-BioNTech COVID-19 Vaccine, Bivalent was approved to supply the third dose within the 3-dose main collection.
- The Pfizer-BioNTech COVID-19 Vaccine, Bivalent contains an mRNA element comparable to the unique virus pressure to supply an immune response that’s broadly protecting towards COVID-19 and an mRNA element comparable to the omicron variant BA.4 and BA.5 lineages to supply higher safety towards COVID-19 attributable to the omicron variant.
“Today’s authorization supplies dad and mom and caregivers of youngsters 6 months through 4 years of age who acquired the three-dose main collection with the monovalent Pfizer-BioNTech COVID-19 Vaccine a chance to replace their youngsters’s safety by receiving a booster dose with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent,” stated Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Currently accessible information present that vaccination stays the most effective protection towards extreme illness, hospitalization and demise attributable to COVID-19 throughout all age teams, and we encourage all eligible people to be sure that their vaccinations are updated with a bivalent COVID-19 vaccine.”
FDA Evaluation of Available Effectiveness Data
For the authorization of a single booster dose of the Pfizer COVID-19 Vaccine, Bivalent for youngsters 6 months through 4 years of age at the least 2 months after completion of main vaccination with three doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine, the FDA evaluated immune response information from 60 youngsters on this age group who had accomplished main vaccination with three doses of monovalent Pfizer-BioNTech COVID-19 Vaccine and acquired a booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent in a scientific examine. One month after receiving the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, the examine individuals demonstrated an immune response to each the unique SARS-CoV-2 virus pressure and to omicron BA.4/BA.5.
In addition, the authorization is supported by the FDA’s earlier analyses of the effectiveness of main vaccination with the monovalent Pfizer-BioNTech COVID-19 Vaccine in people 16 years of age and older and people 6 months through 4 years of age, and former analyses of immune response information in adults larger than 55 years of age who had acquired one booster dose with an investigational Pfizer-BioNTech bivalent COVID-19 vaccine (authentic and omicron BA.1).
FDA Evaluation of Available Safety Data
The security of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent as a booster dose in youngsters 6 months through 4 years of age at the least two months after completion of main vaccination with three doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine relies on the next security information beforehand evaluated by the FDA:
- A scientific examine which evaluated a booster dose with Pfizer-BioNTech’s investigational bivalent COVID-19 vaccine (authentic and omicron BA.1), in people larger than 55 years of age,
- Clinical research which evaluated main vaccination with the monovalent Pfizer-BioNTech COVID-19 Vaccine in people 6 months of age and older,
- Clinical research which evaluated booster vaccination with monovalent Pfizer-BioNTech COVID-19 Vaccine (beforehand, however not, approved) in people 5 years of age and older, and
- Postmarketing security information with the monovalent Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent.
In addition, amongst people 6 months of age and older, security was assessed in individuals in two scientific research. In one examine individuals 6 months through 11 years of age who have been beforehand vaccinated with a 3-dose main collection of monovalent Pfizer-BioNTech COVID-19 Vaccine acquired a booster dose of the Pfizer-BioNTech COVID 19 Vaccine, Bivalent. Among 24 individuals 6 months through 23 months, the commonest unwanted side effects included irritability, drowsiness, injection website redness, ache and swelling, decreased urge for food, fatigue, and fever. Among 36 individuals 2 years through 4 years of age, the commonest unwanted side effects included fatigue, injection website ache, redness and swelling, diarrhea, vomiting, headache, joint ache, and chills. Among 113 individuals 5 through 11 years of age, the commonest unwanted side effects included, fatigue, headache, muscle ache, joint ache, chills, fever, vomiting, diarrhea, injection website ache, swelling and redness, and swelling of the lymph nodes in the identical arm of the injection. In one other examine, 316 individuals 12 years of age and older who have been beforehand vaccinated with a 2-dose main collection and a single booster dose of monovalent Pfizer-BioNTech COVID-19 Vaccine, acquired a second booster dose with the Pfizer BioNTech COVID-19 Vaccine, Bivalent. The mostly reported unwanted side effects by the individuals on this age group have been the identical as these reported by the individuals within the 5 through 11 years age group.
The security information accrued with the investigational bivalent vaccine (authentic and omicron BA.1) and with the monovalent Pfizer-BioNTech COVID-19 Vaccine are related to the Pfizer-BioNTech COVID-19 Vaccine, Bivalent as a result of these vaccines are manufactured utilizing the identical course of.
The reality sheets for recipients and caregivers and for healthcare suppliers embody details about the vaccine’s potential unwanted side effects, as effectively as the dangers of myocarditis and pericarditis.
The modification to the EUA was issued to Pfizer Inc.
Related Information
###
(*6*)
Boilerplate
The FDA, an company throughout the U.S. Department of Health and Human Services, protects the general public well being by assuring the protection, effectiveness, and safety of human and veterinary medication, vaccines and different organic merchandise for human use, and medical units. The company is also accountable for the protection and safety of our nation’s meals provide, cosmetics, dietary dietary supplements, merchandise that give off digital radiation, and for regulating tobacco merchandise.
